News Updates
Scope
Catalyst

Mon, Jun 1, 2026

1 updates
PRAX
4:15 PM

Praxis Precision Medicines Provides Vormatrigine Program Update

POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second half of the study on higher dose (30 mg) was more pronounced Vormatrigine was generally

Trial Results • Phase 2/3POWER1 results Mon, Jun 1, 2026, 4:15 PM EDTpraxismedicines.com

Mon, Apr 6, 2026

1 updates
PRAX
8:00 AM

Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy

Elsunersen demonstrated placebo-adjusted seizure reduction from baseline of 77% (p=0.015) 71% of elsunersen-treated patients achieved >50% seizure reduction by period 6, with sustained benefit observed in the open-label extension for up to one year 100% of elsunersen patients - and none on placebo

Trial Results • Phase 1/2praxismedicines.com